3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma, Renal Cell
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor
1
Pharyngeal Neoplasms
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Erythrocytosis, Familial, 4
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
11
Nivolumab
7
Sunitinib
6
Cyclophosphamide
6
aldesleukin
5
Sorafenib
5
Everolimus
5
temsirolimus
4
belzutifan
4
atezolizumab
4
Ipilimumab
4
fludarabine
3
cabozantinib
3
Interferon-alpha
3
Gene Expression Profiling
3
Fluorouracil
3
Docetaxel
3
Cetuximab
3
Busulfan
3
valspodar
2
sargramostim
2
perifosine
2
pazopanib
2
ixabepilone
2
entinostat
2
ciforadenant
2
belinostat
2
Thiotepa
2
Temozolomide
2
Sirolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Kidney Neoplasms
×
zimberelimab
×
Clear all
NCT05536141
2026-05-01
ARC-20
Arcus Biosciences, Inc.
Phase 1
Recruiting
362 enrolled